嘉越

Jiayue Pharma is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of innovative small molecule therapeutics. The company utilizes a proprietary translational medicine platform to accelerate the transition of candidates from discovery to clinical application, focusing primarily on oncology, autoimmune disorders, and metabolic diseases. Its lead programs include advanced inhibitors targeting FLT3 and BTK, aimed at treating hematological malignancies and solid tumors. Jiayue Pharma is backed by prominent venture capital firms and maintains a robust pipeline of differentiated assets designed to address significant unmet medical needs globally. The company emphasizes a Fast-to-Proof-of-Concept strategy to optimize drug development timelines.